Significant reductions in severe exacerbations when added to SOC1,a
SOC, standard of care.
Significant reductions in severe exacerbations when added to SOC1,2,a
Consistently prevented severe exacerbations in patients with no minimum biomarker requirement when added to SOC1,b,c
No statistically significant differences were observed during the 52-week treatment period in patients with baseline blood eosinophils <150 cells/µL taking DUPIXENT 200 mg or 300 mg + SOC and in the ≥150 to <300 cells/µL eosinophil subgroup treated with DUPIXENT 200 mg + SOC vs matching placebo + SOC.1
- a Severe exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or hospitalization or emergency department visit due to asthma that required systemic corticosteroids.1
- b ITT population was unrestricted by minimum baseline eosinophils or other Type 2 biomarkers (eg, FeNO or IgE).3
- c For inclusion in the study, all patients were required to have had ≥1 severe asthma exacerbation in the prior year. Placebo-treated patients with greater numbers of prior exacerbations had greater numbers of exacerbations during the treatment period. A severe asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids for ≥3 days or asthma-related hospitalization or emergency department visit requiring systemic corticosteroids between the first dose and last dose plus 14 days. Subjects with baseline blood eosinophil levels >1500 cells/µL (<1.3%) were excluded.1,4